AbCellera Biologics Inc. (ABCL) › Operating Cash FlowAbCellera Biologics Inc. (ABCL) — Operating Cash FlowAnnual figures by fiscal year, from SEC filings.2019: $2.69M2020: $22.69M2021: $244.58M2022: $277.36M2023: -$43.88M2024: -$108.56M2025: -$131.29M-$131.29M2019Operating Cash Flow (USD)2025Fiscal YearOperating Cash FlowChange YoY2025-$131.29M-20.9%2024-$108.56M-147.4%2023-$43.88M-115.8%2022$277.36M+13.4%2021$244.58M+977.9%2020$22.69M+742.2%2019$2.69M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per Share